Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy

Experimental data and few clinical non-randomized studies have shown that inhibition of the renin-angiotensin system by angiotensin-converting enzyme (ACE) associated or not with the use of mycophenolate mofetil (MMF) could delay or even halt the progression of chronic allograft nephropathy (CAN). In this retrospective historical study, we investigated whether ACE inhibition (ACEI) associated or not with the use of MMF has the same effect in humans as in experimental studies and what factors are associated with a clinical response. A total of 160 transplant patients with biopsy-proven CAN were enrolled. Eighty-one of them were on ACE therapy (G1) and 80 on ACEI_free therapy (G2). Patients were further stratified for the use of MMF. G1 patients showed a marked decrease in proteinuria and stabilized serum creatinine with time. Five-year graft survival after CAN diagnosis was more frequent in G1 (86.9 vs 67.7%; P < 0.05). In patients on ACEI-free therapy, the use of MMF was associated with better graft survival. The use of ACEI therapy protected 79% of the patients against graft loss (OR = 0.079, 95%CI = 0.015-0.426; P = 0.003). ACEI and MMF or the use of MMF alone after CAN diagnosis conferred protection against graft loss. This finding is well correlated with experimental studies in which ACEI and MMF interrupt the progression of chronic allograft dysfunction and injury. The use of ACEI alone or in combination with MMF significantly reduced proteinuria and stabilized serum creatinine, consequently improving renal allograft survival.

Saved in:
Bibliographic Details
Main Authors: Moscoso-Solorzano,G.T., Mastroianni-Kirsztajn,G., Ozaki,K.S., Franco,M.F., Pacheco-Silva,A., Câmara,N.O.S.
Format: Digital revista
Language:English
Published: Associação Brasileira de Divulgação Científica 2009
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2009000500008
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0100-879X2009000500008
record_format ojs
spelling oai:scielo:S0100-879X20090005000082009-04-27Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathyMoscoso-Solorzano,G.T.Mastroianni-Kirsztajn,G.Ozaki,K.S.Franco,M.F.Pacheco-Silva,A.Câmara,N.O.S. Renin-angiotensin system Mycophenolate mofetil Renal allograft survival Kidney transplantation Experimental data and few clinical non-randomized studies have shown that inhibition of the renin-angiotensin system by angiotensin-converting enzyme (ACE) associated or not with the use of mycophenolate mofetil (MMF) could delay or even halt the progression of chronic allograft nephropathy (CAN). In this retrospective historical study, we investigated whether ACE inhibition (ACEI) associated or not with the use of MMF has the same effect in humans as in experimental studies and what factors are associated with a clinical response. A total of 160 transplant patients with biopsy-proven CAN were enrolled. Eighty-one of them were on ACE therapy (G1) and 80 on ACEI_free therapy (G2). Patients were further stratified for the use of MMF. G1 patients showed a marked decrease in proteinuria and stabilized serum creatinine with time. Five-year graft survival after CAN diagnosis was more frequent in G1 (86.9 vs 67.7%; P < 0.05). In patients on ACEI-free therapy, the use of MMF was associated with better graft survival. The use of ACEI therapy protected 79% of the patients against graft loss (OR = 0.079, 95%CI = 0.015-0.426; P = 0.003). ACEI and MMF or the use of MMF alone after CAN diagnosis conferred protection against graft loss. This finding is well correlated with experimental studies in which ACEI and MMF interrupt the progression of chronic allograft dysfunction and injury. The use of ACEI alone or in combination with MMF significantly reduced proteinuria and stabilized serum creatinine, consequently improving renal allograft survival.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.42 n.5 20092009-05-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2009000500008en10.1590/S0100-879X2009000500008
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Moscoso-Solorzano,G.T.
Mastroianni-Kirsztajn,G.
Ozaki,K.S.
Franco,M.F.
Pacheco-Silva,A.
Câmara,N.O.S.
spellingShingle Moscoso-Solorzano,G.T.
Mastroianni-Kirsztajn,G.
Ozaki,K.S.
Franco,M.F.
Pacheco-Silva,A.
Câmara,N.O.S.
Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy
author_facet Moscoso-Solorzano,G.T.
Mastroianni-Kirsztajn,G.
Ozaki,K.S.
Franco,M.F.
Pacheco-Silva,A.
Câmara,N.O.S.
author_sort Moscoso-Solorzano,G.T.
title Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy
title_short Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy
title_full Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy
title_fullStr Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy
title_full_unstemmed Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy
title_sort synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy
description Experimental data and few clinical non-randomized studies have shown that inhibition of the renin-angiotensin system by angiotensin-converting enzyme (ACE) associated or not with the use of mycophenolate mofetil (MMF) could delay or even halt the progression of chronic allograft nephropathy (CAN). In this retrospective historical study, we investigated whether ACE inhibition (ACEI) associated or not with the use of MMF has the same effect in humans as in experimental studies and what factors are associated with a clinical response. A total of 160 transplant patients with biopsy-proven CAN were enrolled. Eighty-one of them were on ACE therapy (G1) and 80 on ACEI_free therapy (G2). Patients were further stratified for the use of MMF. G1 patients showed a marked decrease in proteinuria and stabilized serum creatinine with time. Five-year graft survival after CAN diagnosis was more frequent in G1 (86.9 vs 67.7%; P < 0.05). In patients on ACEI-free therapy, the use of MMF was associated with better graft survival. The use of ACEI therapy protected 79% of the patients against graft loss (OR = 0.079, 95%CI = 0.015-0.426; P = 0.003). ACEI and MMF or the use of MMF alone after CAN diagnosis conferred protection against graft loss. This finding is well correlated with experimental studies in which ACEI and MMF interrupt the progression of chronic allograft dysfunction and injury. The use of ACEI alone or in combination with MMF significantly reduced proteinuria and stabilized serum creatinine, consequently improving renal allograft survival.
publisher Associação Brasileira de Divulgação Científica
publishDate 2009
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2009000500008
work_keys_str_mv AT moscososolorzanogt synergisticeffectofmycophenolatemofetilandangiotensinconvertingenzymeinhibitorinpatientswithchronicallograftnephropathy
AT mastroiannikirsztajng synergisticeffectofmycophenolatemofetilandangiotensinconvertingenzymeinhibitorinpatientswithchronicallograftnephropathy
AT ozakiks synergisticeffectofmycophenolatemofetilandangiotensinconvertingenzymeinhibitorinpatientswithchronicallograftnephropathy
AT francomf synergisticeffectofmycophenolatemofetilandangiotensinconvertingenzymeinhibitorinpatientswithchronicallograftnephropathy
AT pachecosilvaa synergisticeffectofmycophenolatemofetilandangiotensinconvertingenzymeinhibitorinpatientswithchronicallograftnephropathy
AT camaranos synergisticeffectofmycophenolatemofetilandangiotensinconvertingenzymeinhibitorinpatientswithchronicallograftnephropathy
_version_ 1756391250384125952